Danish Transportation Stock News

Deciding what to do with Rockwool stock? You are definitely not alone—it is one of those companies that always sparks debate among investors, especially after a stretch of ups and downs that has put everyone on alert. If you have been watching the chart, you know things have been anything but boring. After a relatively flat week, the share price has taken a 15.3% drop over the past month and sits down 5.1% for the year. Over the past year, Rockwool is off 14.6%, but zoom out to three years...

TROPHY GAMES Development A/S ( CPH:TGAMES ) shares have retraced a considerable 28% in the last month, reversing a fair...

H. Lundbeck (CPSE:HLUN B) has recently seen its shares catch a bit of attention, even without a dramatic headline to drive the move. Sometimes, the absence of an obvious trigger can raise just as many questions as a major announcement. It prompts investors to dig a little deeper, asking whether traders are anticipating future news, simply reacting to broader market currents, or reading more subtle signals about Lundbeck’s future prospects. Looking back at the year, there has been a...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

GN Store Nord A/S ( CPH:GN ) shareholders should be happy to see the share price up 22% in the last month. But will...

Vestas Wind Systems (CPSE:VWS) just landed a fresh order that is bound to catch the eye of investors weighing their next move. The company announced a deal with Energiekontor AG in Germany, supplying 13 of its V162-7.2MW turbines and committing to a long-term, 20-year service agreement. While this order itself may not shift the industry's foundations, the combination of scale and a substantial service window signals ongoing appetite for Vestas’ solutions in the key EMEA region. This can be...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

It is hard to get excited after looking at DSV's (CPH:DSV) recent performance, when its stock has declined 17% over the...

Key Insights The considerable ownership by retail investors in Pandora indicates that they collectively have a greater...

Cemat A/S' ( CPH:CEMAT ) robust earnings report didn't manage to move the market for its stock. We did some digging...

Investors in Novo Nordisk (CPSE:NOVO B) have just gotten a major jolt with fresh data from the STEER real-world study, presented at the European Society of Cardiology Congress 2025. The company’s obesity drug Wegovy showed a strikingly greater reduction in risk for serious cardiovascular events compared to tirzepatide, among people living with obesity and established cardiovascular disease but no diabetes. With a 57% greater risk reduction for heart attack, stroke, and deaths from any cause...

Nilfisk Holding A/S ( CPH:NLFSK ) shareholders would be excited to see that the share price has had a great month...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But even in a...

Despite posting some strong earnings, the market for Royal Unibrew A/S' ( CPH:RBREW ) stock hasn't moved much. We did...

Sydbank announced results for the half year ended June 30, 2025, reporting net interest income of DKK 1,930 million and net income of DKK 1,207 million, both lower than the previous year, while also completing a share buyback program totaling 1,138,104 shares for DKK 490 million. The bank also issued new profit after tax guidance for 2025, forecasting annual earnings between DKK 2,200 million and DKK 2,600 million, giving investors a fresh outlook for the year. With these updates, we'll...

Embla Medical hf.'s ( CPH:EMBLA ) price-to-earnings (or "P/E") ratio of 28.7x might make it look like a strong sell...

On August 26, 2025, Genmab announced that the U.S. FDA granted Breakthrough Therapy Designation to its investigational antibody-drug conjugate Rina-S for adult patients with recurrent or progressive endometrial cancer who progressed after prior platinum-based and PD-(L)1 therapies. This regulatory milestone spotlights Rina-S as a leading late-stage asset within Genmab's expanding oncology portfolio, reflecting the growing recognition of its promise in difficult-to-treat cancers. We'll...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

There wouldn't be many who think Aktieselskabet Schouw & Co.'s ( CPH:SCHO ) price-to-earnings (or "P/E") ratio of 14.7x...

Key Insights Ørsted's estimated fair value is kr.359 based on 2 Stage Free Cash Flow to Equity Ørsted's kr.200 share...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

Hove A/S ( CPH:HOVE ) shareholders have had their patience rewarded with a 38% share price jump in the last month...

Per Aarsleff Holding ( CPH:PAAL B ) Third Quarter 2025 Results Key Financial Results Revenue: kr.5.75b (flat on 3Q...